EBMT Meeting

Donal McLornan, MBBCh, MRCP, PhD, FRCPath, discusses future research directions for an EBMT machine learning model for identifying and stratifying transplant risk in myelofibrosis.

Kiavasch Mohammad Nejad Farid, MD, discusses the efficacy of MDC-CAR-BCMA001 in relapsed/refractory multiple myeloma and systemic light chain (AL) amyloidosis.

Real-world data with axi-cel, tisa-cel, and brexu-cel in patients with B-cell malignancies proved comparable to other experiences with cellular therapy.

Tabelecleucel generated high response rates and favorable OS in patients with EBV-positive PTLD who had progressed on prior standard-of-care approaches.

Pacritinib was active and safe in patients with multi-refractory chronic graft-vs-host disease.

Axi-cel led to higher response rates but increased toxicity vs tisa-cel in older patients with relapsed/refractory DLBCL.

A consistent ORR was shown with axatilimab after second-line therapy, regardless of prior lines of therapy, in patients with steroid-refractory cGVHD.

Infections occur early after CAR T-cell therapy administration in patients with relapsed/refractory NHL.

Brexu-cel demonstrated clinical activity and safety in patients over 70 years of age with relapsed/refractory mantle cell lymphoma.

D-VRd with daratumumab/lenalidomide maintenance led to sustained PFS and MRD negativity across high-risk subgroups of newly diagnosed multiple myeloma.

Cilta-cel improved rates of MRD negativity and 30-month PFS vs SOC in patients with lenalidomide-refractory multiple myeloma with MRD negativity.

MDC-CAR-BCMA001 may be a suitable construct for the treatment of BCMA-pretreated patients with triple-class refractory multiple myeloma or AL amyloidosis.

Ciltacabtagene autoleucel is the first CAR T-cell therapy to show significant OS benefit in multiple myeloma.

Obe-cel showed higher response rates and longer survival vs non–CAR T therapies in adults with R/R B-ALL.

The addition of inotuzumab ozogamicin to bridging therapy led to high objective response rates and sustained survival in obe-cel recipients with B-cell ALL.

A donor-derived CAR T-cell therapy produced complete remissions, but survival was limited in relapsed/refractory T-cell lymphoma.

Stable disease was common in patients with CD123-positive, relapsed/refractory acute myeloid leukemia who were treated with AFM28.

María-Victoria Mateos, MD, PhD, discusses long-term OS data from the CARTITUDE-4 trial of cilta-cel in lenalidomide-refractory multiple myeloma.

Ioannis Politikos, MD, discusses data from a study which compared the immune reconstitution profiles of Orca-T with those from CD34 allograft recipients.

D-VRd provides PFS benefit and deeper responses vs VRd in transplant-eligible myeloma, according to a post hoc analysis of pooled PERSEUS and GRIFFIN data.

TDI01, a selective ROCK2 inhibitor, generated responses and clinical benefit in patients with cGVHD.

Acimtamig plus AlloNK was associated with high objective response rates in heavily pretreated patients with relapsed/refractory Hodgkin lymphoma.

A comparative analysis showed that apraglutide plus ruxolitinib improved response rates vs ruxolitinib monotherapy in steroid-refractory GI aGVHD.

Orca-T was associated with a retrospective survival improvement vs post-transplant cyclophosphamide in advanced hematologic malignancies.

Orca-T led to lower rates of EBV and CMV reactivation vs CD34 engraftment in patients with select hematologic malignancies.

Higher CR rates were achieved with the tandem CAR T-cell infusion plus ASCT vs the infusion alone in patients with relapsed/refractory B-cell lymphoma.

Juan Carlos Hernández-Boluda, MD, PhD, discusses an EBMT machine learning–based model for identifying and stratifying transplant risk in myelofibrosis.

Improved PFS was associated with at least a 25% reduction in tumor burden before treatment with cilta-cel in patients with relapsed/refractory multiple myeloma.